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This issue of Value in Health presents selected articles
from the ISPOR Second Asia Paciﬁc Conference held in
Shanghai, March 2006. Under the leadership of ISPOR
and the ISPOR Asian Consortium, the ISPOR Asia-
Paciﬁc Conference is held every two years in Asia with
a twofold mission: to help develop knowledge and
capacity for health economics and outcomes research
(HE/OR) in Asia; and to promote the use of HE/OR
in policymaking processes in Asia, with the goal of
improving efﬁciency in the allocation of resources.With
“Improving Evidence and Outcomes in Health Care
Decision-Making” as the theme, the Second ISPOR
Asia-Paciﬁc Conference was well received, achieving an
unprecedented level of participation from the Asian
communities. All articles included in this issue under-
went the usual anonymous process of peer review.
The Asia-Paciﬁc is a very signiﬁcant region in the
world, with the fastest growth among economies in
general and among pharmaceutical markets in particu-
lar. It is also arguably the most diverse region in the
world—home to long cultural traditions and all the
world’s major religions, as well as countries that span
the gamut from among thewealthiest to the poorest, the
largest to among the smallest, and awide array of politi-
cal systems. Health-care systems in the region are very
dynamic and diverse as well. Following Australia where
HE/OR data are required for national policy setting,
countries such as Japan and South Korea have already
moved into the initial phase to recommend the use of
HE/OR data for drug formulary policymaking, and
others suchasChinahaveprofessionalorganizationsbe-
ginning to draft pharmaceutical economics guidelines.
In the meantime, most Asia-Paciﬁc countries also
confront challenges common to countries around the
globe: safeguarding public health, expanding health-
care coverage and improving quality while controlling
costs, fostering value for money, and ﬁnding an appro-
priate balance of government and market roles in the
health sector. To address these challenges, researchers
and policymakers alike will no doubt ﬁnd it important
to increase the analytic and policy relevance of eco-
nomic analysis [1].
In particular, pharmaceuticals and their regulation
play an increasingly important and often contentious
role in the health-care systems of the Asia-Paciﬁc [2].
Countries such as China, Thailand, and Pakistan have
extraordinarily high drug spending as a percentage of
total health spending, leading to drug cost control often
as a major target when reforming policy. For example,
during the current health-care reform process in China,
much debate has been focused on the impact of pricing
control and separating prescribing and dispensing func-
tions. Major changes in the policy setting may well
rewrite the professional roles of physicians and phar-
macists, with modiﬁcations to accommodate cultural
norms and strong economic interests. India and several
other countries host thriving domestic pharmaceutical
industries with global importance, although contro-
versy surrounds intellectual property rights, trade
(WTO, TRIPS), and pharmaceutical pricing within
bilateral trade agreements (Australia-US, Republic of
Korea-US). Nations throughout the region struggle
with appropriate regulation of drugs, from the ethics of
clinical trials to patents, evidence-based purchasing
(e.g., Australia’s Pharmaceuticals Beneﬁt Scheme), and
direct-to-consumer advertising. Deeply rooted tradi-
tions of indigenous medicine are modernizing and inte-
grating into broader health-care systems. Improving
access, effective prescribing and appropriate use of
medications will be central to controlling infectious
diseases, both old and emerging; protecting the global
public good of anti-microbial effectiveness; and treating
the growing burden of chronic diseases for the aging
populations of the Asia-Paciﬁc [2].
There are 20 articles and four policy brieﬁng notes
in this special supplement. The 20 articles are orga-
nized under four sections: 1) economic evaluation
which addresses cost-effectiveness of alternative treat-
ment or use of medications for illness such as diabetes
and other chronic illnesses; 2) cost analysis that
includes estimation of direct illness treatment costs or
intangible costs of illness conditions; 3) health condi-
tions or health-related quality of life among various
Asian population; and 4) policy review articles that
provide drug pricing, drug safety, and pharmaco-
economics research in the Asian-Paciﬁc Region.
These articles represent an important milestone in
the evolution of health economics and outcomes
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research and evidence-based medicine in Asia. Their
signiﬁcance lies in showcasing the growing Asian exper-
tise in this area, as well as highlighting the challenges
that still lie ahead. The selected articles include empiri-
cal and policy analyses from 10 countries of south,
southeast and northeast Asia. Many of the articles
feature international collaborations among researchers,
which can often wed in-depth institutional knowledge
of the Asian context with a comparative analytical lens
that bringsmethodological rigor to bear on questions of
local and international policy relevance.
The contributions featured here cover a range of
health and health-care topics. The continued salience of
burden of disease from infectious disease, especially in
certain parts of Asia, underscores the importance of
studies such as those included here on hepatitis B in
China; intraabdominal infections in India; and shigello-
sis patients in Thailand. In light of the economic, demo-
graphic, and epidemiologic transitions shaping Asia’s
health systems, there will be a growing niche for de-
tailed analyses of cost-effective management of chronic
diseases such as diabetes and coronary heart disease
(thesubjectofmultiplearticles inthisvolume).Policyma-
kers should also be interested in the evidence regarding
the “return on investment” from allocating resources to
prevention, such as promoting healthier lifestyles, stem-
ming the increase in overweight and obesity and its
medical sequelae. To explore such issues requires
careful work on quantifying health-related quality of
life and instruments formeasuring health status that are
appropriate for speciﬁc conditions and contexts yet
generalizable enough to form a foundation for resource
allocation decisions across the health sector. Articles
included here begin to address these challenges.
Finally, decision-makers may beneﬁt from enhanced
tools to measure costs, predict resource use, and
improve budgeting processes. Of course, policymakers
face numerous constraints in using economic analyses
as the basis for policy decisions. Arguably, even perfect
economic analysis based on perfect data cannot be the
sole criterion for most policy decisions. For example,
ethical concerns arise in every phase of economic
evaluation of new technologies and pharmaceuticals,
from the drug discovery and clinical trial process all
the way to resource allocation decisions, provider
agency for patients, and regulation of access [3]. Use
of cost-beneﬁt analyses should be a complement to,
rather than a substitute for, political and ethical con-
sideration of questions of distributional justice.
Institutional development in evidence-based medi-
cine, and regulatory mechanisms to assure safety and
quality, will be other necessary complements to the
enhanced managerial processes that health economics
and outcomes research can foster. Several contribu-
tions focus on these subjects in some depth.
As the knowledge of economic evaluation improves
among researchers, providers, policymakers, and
patients, acceptance of their role in the system may
grow. As Drummond notes, international experience
suggests that “a decision-making process embodying
the formal use of economic evaluation is workable.
Although it would be wrong to suggest that the intro-
duction of economic evaluation has been problem-free,
none of the jurisdictions adopting economic evaluation
has thus far sought to abandon it” [4].
Several areas of investment appear to be needed:
1) Investment in research capacity building in Asia to
continue to improve the depth and breadth of HE/OR
knowledge and communications with international
communities; 2) investment in developing well-
designed, population-based clinical and economic
databases in the public domain; and 3) investment in
adapting methods, models, and other tools to the
Asian context (such as speciﬁc patient populations and
institutional arrangements). Moreover, Asian scholars
should also be challenged to broaden their perspective
when conducting health economics and outcomes
research. In particular, policymakers in rapidly
growing and relatively stagnant economies alike might
greatly appreciate studies on the economic returns
from health investment, in addition to its intrinsic
value [5,6]. Such research would help build a better
understanding and communication between health
and other sectors, thus contributing to the justiﬁcation
for increasing public ﬁnancing for health care.
We hope this collection of articles will inspire more
researchers in Asia to take on this work and encourage
more decision-makers to have conﬁdence in the im-
proving methods and relevance of health economics
and outcomes research for resource allocation in the
health sectors of the Asia-Paciﬁc.
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